Du är här

2015-09-25

Revenio Group Corporation: Increased number of shares entered into trade register

Revenio Group Corporation, Stock Exchange Release, September 25, 2015 at 9:00

INCREASED NUMBER OF SHARES ENTERED INTO TRADE REGISTER

8,522 new share subscriptions based on the company's 2007C stock options
approved by the Board of Directors of Revenio Group Corporation on September
17, 2015, have been entered into the trade register today. The share
subscription price under 2007C option rights was 1.24 EUR per share. The
subscription period for 2007C options is to June 1, 2016.

After these subscriptions, the number of Revenio Group Corporation's shares
and votes will rise to 7,943,811. These increases were recorded in their
entirety in the unrestricted shareholders' equity fund.

Revenio Group Corporation has applied for the listing of its new shares on the
Nasdaq Helsinki in the same series as the company's existing shares.
According to the current estimate, the new shares will be listed on September
28, 2015.

Revenio Group Oyj
Olli-Pekka Salovaara
CEO

For further information, please contact:

President&CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:

NASDAQ Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is in tonometers.
The Revenio Health Tech segment comprises the business operations of Icare
Finland Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in
osteoporosis screening and monitoring. The common denominators of Revenio's
business operations include screening, follow-up and the global need to make
cost savings in health care via preventive measures. Revenio seeks vigorous
growth in health technology, both organically and through acquisitions and
mergers. Revenio aims at developing even more efficient and easily adopted
methods for the early-stage detection of diseases with significance for
public health. The focus of Revenio's screening technology lies on the early
detection of glaucoma, osteoporosis, skin cancer and asthma, and the
monitoring of these during the treatment process.

In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating
profit (EBIT) from continuing operations standing at 27.5%. The Revenio Group
Corporation is listed on NASDAQ OMX Helsinki.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Revenio Group Corporation via Globenewswire

HUG#1953313

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.